LEMTRADA alemtuzumab

Drug Class

CD52-directed cytolytic monoclonal antibody

Mechanism

Alemtuzumab binds to CD52 on B and T lymphocytes, causing antibody-dependent cellular cytolysis and complement-mediated lysis, depleting circulating lymphocytes to reduce neuroinflammation.

Approved Indication

Treatment of patients with relapsing forms of multiple sclerosis (MS) who have had an inadequate response to two or more therapies.

What This Means For Patients

LEMTRADA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2014) — Sources
• EMA — Approved (2013) — Sources

Pivotal Clinical Evidence

• CARE-MS I — Cohen et al., Lancet 2012 (NCT00530348) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada
• https://doi.org/10.1016/S0140-6736(12)61769-3